Expert Briefing: Disease Modification & Stem Cells: Where Are We Now?
-
Dr. James Beck 00:00:00
Hi everyone, and welcome to the Parkinson's Foundation expert briefing. I'm Dr. James Beck, Chief Scientific Officer of the Parkinson's Foundation, and it's a pleasure to have you with us today. In today's briefing, we're going to hear an overview of where the field stands, exploring breakthroughs in disease-modifying therapy, and learning how researchers are working toward interventions that could slow, stop, and maybe even reverse the disease process. But before we get started, I'd like to get a sense of who's joining us today. We're going to launch a poll like we typically do, and if you're joining on Facebook Live, please remember you can respond using the comments section. So the poll is just launched, and so please identify yourself.And if you're more than one of these, you can select more than one. So person with Parkinson's, a physician, a clinician, other family members here supporting your person with Parkinson's as part of the process. And if you're not on this list, just feel free to click other, and then you can enter it into the Q&A box as well, so we can get it just get a sense. It's always really interesting to see and help guide our discussion today to see who is here joining us from around the world as part of the process and what area they represent. Ah, great. A lot of people with Parkinson's and their and their care partners here.
And a lot of other people associated with PD as well. Great to see all those individuals, and a handful of people put an answer in as other. So interesting to see those in a bit, what those may be. So thank you for sharing your connection about Parkinson's. But before we begin our formal briefing, I always like to take a moment to introduce the Parkinson's Foundation. We are a nonprofit organization dedicated to improving the lives of those living with Parkinson's by enhancing care and advancing research. Our efforts are deeply rooted in the collaboration with the Parkinson's community, ensuring that everything we do aligns with your needs and priorities.
I think today, as always, is a great example of how we're working with you to meet those goals. I'd also like to take an opportunity to introduce a new feature on our website, Ask PAM. It's our Parkinson’s assistance messenger. PAM is an AI-powered chat tool from our foundation that provides trusted, evidence-based answers about Parkinson's disease anywhere, anytime. It's secure, it's confidential, and it was created to give people with Parkinson's and their caregivers instant access to Parkinson's Foundation-rooted information, 24 hours a day, seven days a week. The information contained in PAM is what's within our website, so you don't have to worry about random things that have been coming from elsewhere on the web.
It's all been reviewed and approved as part of the process. Of course, with PAM, it's just educational information provided, and it shouldn't replace expert medical advice from your healthcare provider. And as always, a reminder that we're going to record our expert briefing today. And the recording will be available online shortly, so we'll automatically send you a link when the recording is available, as well as resources for topics that we discussed today. Now, as we begin, I'm really pleased to introduce our speaker today. Dr. Michael Okun is a world-renowned neurologist and movement disorder specialist, recognized as a leader in Parkinson's disease care research and advocacy.
Dr. James Beck 00:03:12
He was chair of neurology at the University of Florida before he co-founded and became the executive director of the Norman Fixel Institute for Neurological Disease, also at the University of Florida. He coined the term Parkinson's pandemic to raise awareness of the rapidly growing impact of Parkinson's disease. And he has played a key role in advancing interdisciplinary care research and treatment innovations. He's published more than 600 peer-reviewed articles, authored 15 books, including the Parkinson's Plan, and is a frequent spokesperson featured in major national media. His work has helped shape new therapies and improve the lives of people living with Parkinson's, not only in the U. S. but worldwide.Dr. Okun has also worked closely with the Parkinson's Foundation since 2006, where he's been a national medical director and advisor to the foundation. He currently serves as chair of the foundation's clinical advisory council. This year, he also became a member of the advisory council for the national plan to end Parkinson's, providing his input and guidance to the national effort to tackle this disease. Dr. Okun, it's a pleasure to have you with us today. And for today's expert briefing, we're going to do things a little bit differently. We've received hundreds of questions from people living with Parkinson's, their caregivers and health professionals, asking about the latest therapies to stop Parkinson's and about stem cells.
And so today we're going to try to address those themes that we've heard most often. So the format of our briefing will be a little bit different. We're going to be focused on conversations with Dr. Okun and me, all without PowerPoint slides. So if we cover or mention any specific sources or resources during our discussion, my colleagues will note them and will include them in the follow-up email that will accompany the recording. So let me take this moment to say hello and to welcome Dr. Okun. And let's begin with a term that I think is going to be one that's going to really define our conversation today. And if we get Dr. Okun on camera, I see him. There we are. Excellent. Excellent. How are you doing, Dr. Okun?
Dr. Michael Okun 00:05:11
I'm doing great. It's great to be with you, Jim. And what a great series and program that you have. And super excited to be here to chat with you today.Dr. James Beck 00:05:21
Yeah, thanks very much. I appreciate that. So, you know, one of the questions that we have, as we wanted to like define our session today, is about disease-modifying therapies. So this something that you know you and I talk about and we hear about it at conferences, but I don't think it's something that you know the average person with Parkinson's hears about, and so. If you could, for us, can you define what a disease-modifying therapy is and what it might be? Yeah.Dr. Michael Okun 00:05:46
So one of the things that I think is really important is to make sure that as we speak the language, people are understanding, you know, like what we're talking about. And you know, when we talk about you know what can we do for folks, I like to think of it in three simple buckets. The first bucket is symptomatic therapies. So these would be things like drugs, or devices, or exercise, or behavioral treatments. That would be bucket number one. Things that are going to help you potentially today with your symptoms. Bucket number two is: Could we introduce some sort of therapy that wouldn't be necessarily designed to give you symptom relief from something, but would rather slow disease progression?That's what we're talking about when we're talking about disease modification. Bucket number two, could we slow it down? And slowing it down could be very important, and could have many benefits down the road. Bucket number three is the most difficult bucket. People call it the C bucket, the cure bucket. We know that Parkinson’s isn't one disease, and so we're very careful about how we use the C word, particularly because we want to be realistic with folks that are out there. And we do think about things that can be more precise. So we think about precision medicine. So I think of it as the P bucket, not the C bucket.
Meaning, can we have more precise therapies that may target something quite specific, and it might actually help with both disease modification or push us a little closer to cure? Although we always are very careful when we use the C word.
Dr. James Beck 00:07:21
Yeah, I can appreciate that, and I think we already have bucket one going right now, right? We're symptom relief. We have medications available that can be improved. I think that's without doubt, especially around many non-motor areas, about that. You know, slowing progression. What might that mean for a person with Parkinson's? Does it mean that their disease might stop? Or it just, like we may see with MS, it goes in the background, but as you've as the name just says, just at a much slower rate. As part of that.Dr. Michael Okun 00:07:53
Yeah, and what's really interesting is we've evolved in the way that we talk about this, and the way that we explain it, and the way that we frankly understand it as experts. I think early on in the process, were doing a lot of science, and were talking a lot about how do we protect your brain cells from dying. And when we do that, people would use this term called neuroprotection. You know, could we protect them from dying? That sounds good to me. You know, sign me up, right?I mean, it's it's a it's a you know could be a good term, but it became somewhat confusing because it turns out in different studies we can actually save brain cells but not change symptoms, and particularly in humans when we test in humans versus in animals. And so the field really modified, Jim, and we sort of you know took a lesson in humility and began to describe this more as you know could we meaningfully change the progression of a disease? Could we slow the disease progression, change it in some way? Alleviate symptoms that could, you know, in some way impact the overall outcome for an individual person.
And so we've really shifted to use the terms disease modification, okay, and instead of neuroprotection. And a lot of our clinical trialists and people who are really, you know, fantastic at putting together these types of studies now think really hard about how we can design our studies so that it can make a difference. And the tail end of your question is this: Why does it matter? The answer is it matters a lot because if we understand, you know, and we have the right endpoints, and we're able to measure how things are going to change over time. It can give us, you know, some tractable ways, not only for treating something, but for slowing it down.
And if you slow down a disease like Parkinson’s disease, for example, and there are a lot of diseases out there in medicine. I just happen to be interested, as you are in Parkinson. If you slow this one down for many years, we're really good at treating it in a lot of ways, thanks to the research that's come. And so this can be quite meaningful for people and make it an even more livable disease. And it's a myth to say Parkinson’s isn't livable. We have a lot of people that live with Parkinson. But boy, Jim, if we could slow the disease progression, modify it, this could be huge.
Dr. James Beck 00:10:15
Yeah, I think that's for sure the case. I mean, we all know people with Parkinson's who've been living very well with it for a number of years, but I think they would be more than happy to stay at a very slow trajectory if they could, and then let life catch up with them for the end part, right? I mean, yeah, yeah.Dr. Michael Okun 00:10:34
And one of the things for folks that are listening too, just to kind of pile on to this, you know, because I think it's a really important discussion, is when we talk about disease modifying therapies, the thing people make these most surprised about that are watching is there may not be an immediate wow effect, okay? And the wow effect is, oh my gosh, look at all these symptoms that are getting better. And so that actually is really important for us to educate folks on. We're not looking for the immediate wow effect in symptoms. We're looking for slowing progression.And sometimes when there's a wow effect that on something that might also slow progression, it makes it harder for us to measure that. And so we need to have reliable endpoints of these trials, and we need really expert people in this field to help us to define them with markers of how things change. You know, when the biology, sort of all the different science changes in your brain, and we think about how does the disease modifying thing does it get to its target in the brain, and is there. An effect that happens in the sciencey stuff that's going on, but also in slowing progression, and sometimes it's not that big wow that we're looking for.
Dr. James Beck 00:11:47
Yeah, I think that's definitely a case, especially as we think about the trials that may be coming for the disease modifying therapies. Having people recognize it's not going to be like a Lazarus effect, and all of a sudden their symptoms disappear. And to your point, I've heard time and time again from trialists that if a drug really produces that wow effect, everyone is very skeptical that it's actually a disease modifying effect. That it's just symptomatic. It's a very good symptomatic treatment. And so you bring up really good question, and I think it's important for us to we think about how close are we achieving this? Endpoints are something you've mentioned a couple times so far.You know, trying to define what those right endpoints are, I think, are going to be important. How do we measure that success? What do you see as, you know, advances we're making in that? Because, you know, 10, 15 years ago, were really limited in how we could do it. But I think things have changed. Have they not?
Dr. Michael Okun 00:12:46
Yeah, I think so, and I would say I'm I'm pretty optimistic about what we see. You know, I would definitely be thinking, you know, when you think about some of these advances, and people sort of delve in. First of all, it's great to have people, you know, putting their hands into the pot and saying,"Let's get let's get dirty on disease modifying therapies," and start to think about the things that we can do. And so there's at least four things that I would highlight, you know, for people to think about. First is this idea of biomarkers, markers of disease. So if you can measure how something changes, it's like in business.If you can measure the money going up or the money going down, you can kind of tell what's going on. Might surprise people to know we struggle with that and diseases like Parkinson, and so we're getting better now at defining by biology rather than symptoms. And so keep your eye on that. That helps us a lot in this discussion. The second thing is actually genetics, and you know the Parkinson’s Foundation has, you know, really, you know, had a tremendous impact in this area with PD GENEration and getting people genotype. That's sort of what not what your Levi’s look like, but maybe the size and all the differences about your genes.
And it gives us what I call a tractable pathway, you know, to you know more precise treatments and understanding biology. Two great examples are the LRRK2 mutation and the GBA1 mutation. And even though the single genes are the minority of Parkinson. Make no, you know, make no bones about it, Jim. There, it's this really important to helping us to guide the field, and when we're thinking about disease modification. The third thing I think about is alpha-synuclein, and alpha-synuclein is sort of that big bad protein that likes to clump up, and it's moved from like this observation in autopsy studies and in pathology. You know, it's moved all the way from that now into something that.
You know, we can now observe something that we can now begin to measure, and something that might even be what we call a druggable target, something that we can go after with with a type of therapy. Now, you know. The trials are challenging, you know, Jim. But this a real, you know, like a big advance to be thinking about. And then on the fourth thing to think about on disease modification is there's a lot of investigators that have been really interested in cell replacement. And there have been challenges, you know, over the years with this, but it's really moved from an idea to small transplantation studies to now some standardized protocols for dopamine replacement that are being tested.
And you know, the real question is that if we can get better trial designs, better digital measures, better imaging, better stratification by the biology, by the science that's going on in there. You know, can we not only in isolation, but even with these four things in combinations, be thinking about some of the advances that might drive our thinking to how we can get to disease modification?
Dr. James Beck 00:15:49
So I think those are great, and I want to start, if we can, just go into a little bit about you know replacing or protecting these dopamine neurons through stem cells, but you know, one of the things I think about as we talk about these different potentials, a lot of press comes around about that. And how are you talking to people to advise them about, you know, separating the wheat from the chaff? What's the experimental promise versus a proven clinical benefit? Are we there yet for any of these things you see? And I think about. Particularly in the in the case of stem cells, because I think we're getting closer to phase three trials for some of these, and I'm I'm curious your thoughts about are we beginning to see potential promise of some of these therapies?Dr. Michael Okun 00:16:34
Yeah, I think it's really important, and I think that the dialogue on this the most important thing, and the education. And you know, and you and I have been around a long time, you know, probably right about the same amount of time now. We're probably, you know, bumping up on a quarter century, Dr. Beck. And so we've seen from, you know, from the last 25 years or so, the big promise was stem cells are going to cure Parkinson's. And there was even a big movement, you know, a couple of decades ago that were going to have it done within five years. And everybody says, oh, we're going to get it done in five years, right?And you know, here we are. Fast forward. Maybe, you know, we eat a little bit of humble pie, and we say it's a little bit more complicated than we thought it was. But it doesn't mean that we didn't make progress. It doesn't mean that, you know, there aren't good things going on in the stem cell arena. The worrisome thing has been that there are therapies that are out there that people offer for stem cells that are either infused through an IV, sometimes infused into the spinal cord, you know, the fluid that bathes the spinal cord or the brain, that are not under a research protocol, that are not being hypothesis-driven testing, and that have some safety issues.
And some of these have been shut down by the FDA and regulatory agencies all over the world. And there is a term for this, and I, you know, listen. I always say I'm a I'm a cabinet advisor to every person that I see. I'm a neurologist, so I get the honor of seeing people in the clinic. So I never get mad at anybody, no matter what they choose. I'm here to help you to make decisions, to give you information, and if you decide you want to go get a stem cell therapy. It's not like we should abandon you. We're going to embrace you and try to help you.
But we do want to educate and let you know that there is something called stem cell tourism, and that's where folks charge you out of pocket, you know, sometimes substantial amounts of money, tens of thousands of dollars. We've seen people mortgage their houses off, you know, for this for the stem cell cure. And so, if you're promised a cure, you know, if there was a cure, guarantee it, Dr. Beck and I are going to give it to you. Okay, so you know, so there is no cure. Okay, and then the question is, is you know, what is it that they're giving? And we always tell people, look first for registration on something called ClinicalTrials.gov.
And that's where we see a lot of the randomized studies that need to be registered there to be published in major journals. It actually doesn't exclude that there can be scams or stem cell tourism on that site, but it's a good first step. The second step is asking the person that you're seeing, just ask them, give me a copy of your protocol. How are you doing this for each person that you're seeing? Give me a copy of your protocol and copy of the informed consent. Let me think about it.
Dr. Michael Okun 00:19:22
Don't make a snap decision and take it to, you know, somebody in the medical field, maybe your doctor, somebody that you trust, or somebody at the foundation, and show that to them and just get some feedback on it, no matter what you decide. The third thing is, is that making sure that if you're receiving a stem cell therapy and it hasn't been proven, and as you just said, they're in trial, so it hasn't been proven. In general, we think that it straddles that ethical line of should we be charging people for something, you know, if it's still in research. And a lot of times we're paying the research subjects to participate for their time and their hotels and everything until.We prove that a therapy works, and so we always say be cautious if the money's going the other way, particularly if it hasn't been shown. And so we think if you do these things and you think through these things that they're very important. We have become concerned. We have a great 1-800-4PD-info helpline. We're always concerned when people get therapy and they think it's going to be a cure for Parkinson’s disease. And they have what we call a peak of inflated expectations. So anytime a new therapy comes on, there's this peak up of like this should do all of these things. And then when it doesn't, people can become very depressed.
They can become very demoralized, which are already can be baseline challenges with Parkinson. And I've had several people that I know that have committed suicide after receiving a stem cell transplant with the hope that it was going to do something that it didn't, and so with all of those things, I always tell people, make your decisions. You know, we totally embrace you to just take the information, make the decisions. We're not against stem cell therapy. You know, we're actually excited by a lot of the science and what we're learning from the dopamine science. We're excited by a number of trials that are going on across the globe.
We're excited that in Japan there is a limited approval, regulatory approval, with the first seven patients. So in Japan you can apply. They applied with seven patients. They're going to get seven years. I don't know what the magic number seven is, but they seven patients, seven years. They're going to have some data, so at least they'll be able to. But they have to do it in a very careful, controlled format to collect that data and show the rest of the world. And then there are several trials that are going on throughout the United States, and I think there are some real advances that have happened in the stem cell science.
But yeah, thanks for asking because I think it's just important for us to educate. But listen, if you've had a stem cell transplant, if you decide to get one, we should never abandon you. We should we should you know take care of you. Just know like the information that we know. Just you know roll it through your brain and make a decision that makes sense for you.
Dr. James Beck 00:21:58
Yeah, absolutely. And you know I know of at least three companies in the U. S. which are, you know legitimately taking a very serious approach to do just as you said, a very concerted and measured approach for doing stem cell therapies with trials that are coming, and I think it's important. Also, I don't know if you can do this, Michael. Just give us a sense of like, what is a stem cell therapy going to do, and what is it not going to do for a person with Parkinson's? I mean, nothing's been approved, so we're still waiting on the final answers. But what do you think? What do we anticipate will happen from a successful stem cell transplant using in one of these companies that are, you know going through the FDA proper channels with the FDA to get approval?Dr. Michael Okun 00:22:41
Yeah, so I think, you know, very good question, and I think worthy of digging into a little bit. And you know, the first thing that I would say is when you're thinking about a stem cell therapy, think about there's a difference between protecting cells, you know, from dying, and replacing cells. Okay, so that there, you know, that I think is an important distinction. The second thing is just to remember historically. Remember, I told you Dr. Beck and I are old, and so we've we've we've been around to see even transplant trials going back to Mexico and other things with fetal transplants and all sorts of really interesting science over the years.We've seen several failed human trials of that actually had some symptomatic benefit, but also had a side effect called runaway dyskinesias. These are transplant trials. They put cells into the brain. What's the difference in a in a stem cell? Well, stem cell is it's kind of like your kids, right? You know, it's like one of those early cells. You don't know what they're going to be when they grow up, right? You know, they haven't differentiated yet. So it's like one of these very early undifferentiated cells that has a tremendous amount of promise and potential. And we're super good now at handling these cells. We can take skin cells, turn them into stem cells.
We used to need embryos, you know, in order to make the stem cells. Now we can make them in something called autologous stem cells. We can take them from you. We can take them from yourself. We can take them from other areas. So we've gotten very good at making them and also at differentiating them. And there are some very good scientists all around the world who have really done this. There's a great Nobel laureate that's in Japan that's very famous for this and I think it's important to sort of now remember, you know, when we think about replacing, the first thing that we're doing is we're putting a cell into the brain, okay?
And the cell that now we're putting into the brain is called a stem cell. It's the cell with a lot of great promise. So now it's going to matter, Jim, where you put that cell, okay? And so there's been a lot of attention on this. You put the cell in the area that where the dopamine cells are dying, for example, and that's the you know Latin for black substances called substantia nigra. You don't need to know that or remember that, but that's where the dopamine is, the black area. Or do you go up where the dopamine is sending its signals up or projecting up, and do you go upstream to that into another area of the brain called the putamen?
Dr. Michael Okun 00:25:06
And so, all of the regions of the brain are like islands. I think of them as interconnected islands with an amazing communication system, way different than the gallbladder. My apologies to anybody that studies the gallbladder, but the brain is really cool when there are all these circuits. So Jim, it's going to depend on where you put that cell within the circuit. So now you're going to take a cell that has a lot of promise. You can turn it into a dopaminergic cell. You can put it into the circuit. Now, when people put it into that particular circuit that I just described, they're going to see effects on the motor system.Whether you transplant a cell that's just a simple transplant, or you transplant a stem cell, it's going to work on those structures and those projections to try to improve the overall Parkinson. And so, when we think about motor symptoms, and we look at you know like studies that have come out of Sweden, and studies that came out of Denver, and with Stanley Fahn, and his work that was published in the New England Journal, and also Warren Olanow and their trial. If you look at all of those trials, predominantly the benefits that we're seeing were in the motor symptoms: tremor, stiffness, slowness, rigidity.
Makes perfect sense because that's what that circuit is mainly for. Not completely, but mainly for. So, long answer to a short question. Your short question was, what do you expect? I expect if you put any cell, including a stem cell, into these areas where multiple of these companies in Japan, in Korea, in the United States, you know, in Sweden, you know, if you put it in there, you're going to see predominantly motor effects on Parkinson's disease, and so tremor, stiffness, slowness, rigidity. You might pick up some of the other things because there are some other projections, but that's the main things that you're going to see.
And so, why is that important? It's important because I think folks that are thinking about having a surgery, you know, done should think through. I like to say, I know it's a cliche, but I always say, "Is the juice worth the squeeze?" And I really like to think about it if there's going to be a brain surgery associated with it. And so that's kind of how I think through it.
Dr. James Beck 00:27:16
Yeah, absolutely. I mean, I think you hit the nail on the head. And what it sounds like is we're actually not going to alter the disease itself. I mean, we're just talking about really a good way to manage symptoms as part of the process because, the way you've described it, we're not really tackling the underlying cause of the disease.Dr. Michael Okun 00:27:37
Yeah, and I would say, when we think about these strategies, look, everybody who's listening today, this is where we're putting stem cells today. Okay, this isn't the only place to put stem cells. We've learned a tremendous amount. We had to learn about how to turn them on and off because what happens to any cell is, if you can't turn it on and off, it keeps dividing and getting bigger and bigger, one becomes two, two becomes four, four becomes eight. Then you get a cancer, right? So we had to figure that problem out. Scientists have figured that out. We had to figure out why we put them in some people.When you get the extra dance-like movements, dyskinesia, even when you're not on your medicines, yeah, they had to figure out that problem. So they began to figure that out. But the other thing is that think about it this way: we're like in Genesis, the first page of the Bible, you know, on this, right? So if you have other regions of the brain that we can work on, what we call regenerative medicine, where we can put some of these cells into them, then start thinking about some of these other things.
You know, so we wrote about a little bit about this in the Parkinson Plan by talking to Roger Barker and to many of his colleagues, thinking about these memory circuits, for example. Think about the walking circuits and things. And so, so you know, I would just say, I know we're in a rush. I always think of that guy standing on top of the world, looking at his watch, like,"Hurry up!" You know, I've got Parkinson's, you know, but we are making progress.
And when it comes to stem cells, I wouldn't limit the thought process to just that one circuit and just those motor areas, but I would, if you were considering a trial now, be thinking about those as the most tangible things to benefit, and also that there's no evidence that they're disease-modifying, okay, and meaning they slow down the disease, and so just because you get a stem cell, it doesn't equal disease modification. And so I want to make sure that I stress that for people. Now, if one day they do show that it does, that's great.
And I'm all for it, but right now the evidence from 25 years of, you know, more than 25 years of transplant trials and the stem cell trials that we have now is that they can be powerful, but they're not disease-modifying. And so we just need to be honest as to where we are.
Dr. James Beck 00:29:49
Yeah, and I think one of the things that we've seen from the science that indicates that we're not actually stopping Parkinson's is that sometimes these stem cells can actually start showing accumulation of that protein you mentioned, alpha-synuclein. And so maybe it's worthwhile just talking a little bit more about alpha-synuclein, and what do you think where we might be standing on potential discoveries that may play a role, and, you know, controlling alpha-synuclein.So you mentioned it briefly, but maybe it would be worth just giving a little bit more detail about this protein that we often talk about in the in the context of Parkinson's disease. Yeah.
Dr. Michael Okun 00:30:28
So there was this amazing story that happened in a journal called Science way back in the 90s, and they had seen a family of people, an Italian and Greek family, and who all had Parkinson, and it seemed like there was some genetics involved in it. And in those days, they didn't have a lot of PCR, you know. They didn't have all these great technologies we have now. And so, the way you would do it in the old-fashioned ways, you would link people together, and you would draw maps, and you would figure it out, and you would go look, and you go find the gene.And there's a guy named Mihael Polymeropoulos, who published a really important paper with a number of colleagues. It was a co-discovery where they actually saw in this family called the Contursi kindred that this protein called alpha-synuclein was, in this particular case, it had not only doubled, it had tripled. It was called a triplication. It was super interesting, and they were getting Parkinson, and that was a major clue. And so, when people think about it, how we talked a little bit before about PD GENEration and how important genetics are to Parkinson, this was super important.
And if you go back and you read that article, and we recently went back and read it before we were writing on one of our books. If you go back, read the article. It's a great article, and they speculate, "I bet somebody in the next six months to a year is going to see if this Lewy body that gets deposited in Parkinson is this protein, this synuclein." And of course, within a year, multiple groups had shown it. Off to the races.
And so what we have seen is this progressive understanding that there's something very important about this particular protein in the brain, and it sits, you know, maybe near the center of some of the Parkinson's biology, and it folds in different ways, and when it folds in abnormal ways, it can form these clumps. And it can actually spread like a virus by its folding, which is also another interesting thing that many investigators have looked at. And we know the genetics implicate this pathway as well. And so it has sort of allowed us, you know, a you know, it's like a it's like a breadcrumb.
If you were investigating the crime, it's a breadcrumb to go back and figure out what's going on. And now the idea that we can use this as a marker in some folks. Now, not everybody with Parkinson has synuclein pathology. Doesn't have these abnormal protein clumps, but most people do. And so, being able to identify that in living people has made it attractive. And people have, Jim, I think, really, you know, on the first blush said, "What if we could reduce the formation of synuclein?" Right? That's one thing they said. That sounds good, right? You know, sounds bad, clumps up. Let's reduce the formation.
Dr. Michael Okun 00:33:11
People said, "What if we can reduce its ability to aggregate, to clump up?" Another, I mean, like go for it. Sounds like that could be important too. What if we could impact how it spreads from cell to cell? Because that's been one of the mysteries of Parkinson. Like, why? How does it spread? So why does it start? Why does it spread? Why does it progress? And then also people have looked at the toxicity, you know, like is it a good thing or a bad thing? Is the brain trying to throw this away with its garbage system, the garbage disposal in your house? You call it garbage disposal in these cells.We call it a lysosome, if you ever hear that term. And so people have really looked at can we develop strategies to reduce formation, aggregation, spread, and you know looking at the toxic elements, toxic or not. And some groups have even suggested the avant-garde idea that maybe you actually need more synuclein and you know the good form and not the bad form of synuclein. And so when we think about strategies, in my mind, I think about, you know, could we reduce production of alpha-synuclein, and how will that impact symptoms? And then getting back to our original discussion, is it symptoms or is it disease modification?
Could we prevent misfolding? Could we prevent the clumping or the aggregation? Could we enhance how the protein gets cleared out of the brain? You know, the garbage disposal systems. Could we use antibodies, you know, to limit, you know, the spread of this, you know, this bad protein? And you know what's actually interesting and should be very, I think, inspiring to the people listening today. All of the things I've said, scientists are trying and have tried, and I think it's an important piece of the process for us to use this protein to try to understand what's going on.
And then the other really, I think, fascinating and insightful things that people should be inspired by is that we now have tools that Dr. Beck and I didn't have 25 years ago to look at things. It's like think about a great magnifying glass, a great microscope. You know, it turns into what we call a confocal microscope, electron microscope. The tools are getting better and better, and this is so important because Dr. Beck and I are stuck at the end of this stream, watching all of these things, you know, happen and aggregate, and all of this toxicity and everything.
And we're looking and we're saying, "What's going on here?" And we're looking at what's aggregated here at the end of the stream. But now this generation of researchers, many of whom are funded by the Parkinson's Foundation, can use these new tools to begin to look up the stream and see what's going on, maybe even before this aggregation step. And so I think the other exciting thing is synuclein is important, we think. But, you know, what are the few steps that are going on before that and our investment in those tools and the young researchers to get at that is going to be I think really important.
Dr. James Beck 00:36:22
Yeah, absolutely. I think so too. And it's interesting as we talk about you know that initial example you gave of alpha-synuclein and finding this these kindreds for people who make you know more alpha-synuclein than normal. It shows that just too much of a good thing is a bad thing in this particular case, and it leads to Parkinson's disease because their alpha-synuclein is perfectly fine. They just make too much of it, and that has led to Parkinson's disease. And so I think that makes a nice segue for us to talk about like another one of the areas you brought up, which is you know genetics and precision medicine. I know you're excited.I'm excited by it. We've, as an organization, we've invested a lot into genetics and genetic testing in Parkinson's. Why, for you, Michael, why do you think is precision medicine so exciting, even though it's so few people who may actually have that clear genetic link to the disease?
Dr. Michael Okun 00:37:19
Yeah, so well, thanks for asking because I kind of want to set the record straight a bit here. You know that a lot of people, because a lot of things that we've been doing, you know, recently in our lab and with collaborators and with Ray Dorsey in our books, talk a lot about environment. And I think environment is really important. But I remind the geneticists that the genetics are still central to the story, and you know, and so important to us understanding. It's like having the roadmap of what's happening, and we now understand that Parkinson's biology isn't a simple plumbing problem.You can't just remove one bad protein and have the disease disappear. And so understanding you know the circuitry, how it works, how things engage in the target, and then designing, you know, therapies is really important. And some of the downstream damage may have become partly self-sustaining for what's going on in the process, and so the genetics, and I can't emphasize this, you know, enough to the folks that are listening. The genetics give us the biological foothold. It's like, you know, a cleat, you know, to step in the ground, and you like get your, you know, you get a footing on it, and it has given us that foothold.
For example, the LRRK2 mutation, which comes up quite commonly in PD GENEration, you know, it points toward an enzyme, an abnormal enzyme, and it turns out that enzyme is important for signaling, and they call it kinase signaling. And when you look at that signaling, it also is important to like tracing down, and then can you be more precise toward the therapies? And oh, by the way, as we begin to look at the genetics and those pathways, they also seem to have some conservation among all of Parkinson, and so understanding that might actually help us to unlock the larger puzzle.
Another one that comes up on PD GENEration is called the GBA1, you know, mutation. This is from a disease called Gaucher's disease, and it's really interesting, you know. And in our pathway in the last 25 years, I used to see Gaucher's patients every once in a while in the clinic, and a couple of these things that we actually didn't quite understand how common this was in Parkinson to have these GBA1 mutations, and that is the garbage disposal mutation. It's part of that thing we call the lysosome.
It's just the big word that describes the garbage can, and there's an enzyme called glucocerebrosidase, and if you can you know push that enzyme up, yeah, right, exactly. And so it turns out that if you can you know you know kind of put some hyperdrive, some warp drive you know onto that glucocerebrosidase it might be a potential way to improve. In LRRK2 we can target those kinases, those signaling pathways, and so some people talk about personalized medicine, and I think probably the better word I think you'd use it is precision. You know, precision medicine. Could we be more precise, you know, to this?
Dr. Michael Okun 00:40:35
And regardless, and in fact, what's really cool is this study that's going on now in the UK that is with the Cure Parkinson Trust is looking at people with GBA1 mutations and using a cough medication that contains something called ambroxol in it, which kind of soups up the glucocerebrosidase, right?And particularly at the higher dosages, and you know, to their credit, they're testing it both in folks who have GBA1 Parkinson and folks who don't have GBA1 Parkinson, and so I think this is going to be important as we begin to become more precise to understand this and to understand the clusters of cases and who may be you know responding and who is not responding. And a genetic subgroup might be you know one of the cleanest places that we have to prove a mechanism that a therapy, you know, could later be expanded to mutation carriers.
And so, when we look at these things, I think LRRK2 inhibition, I think the ambroxol story, and pushing up the GCase. These, I think, are really important. And then, you know, I'm not just imagining. I mean, I might be hallucinating. It's possible. My wife sometimes says I hallucinate, but you know, I'm pretty sure. I've lived through an era now where, when we watch TV, they weren't talking about gene mutations and precision medicine for oncology and for cancers, and now they are. And so, when you have an organization like Parkinson's Foundation that invests a tremendous amount into individuals to allow them to get their genotype.
When you have an organization that does that, then you have that information. And guess what? It's going to be important, you know, potentially to them, guiding them to clinical trials and maybe one day to therapies. And we saw this progression, and it takes time. I know that's the part that is frustrating for folks, but I think the investment is very worthy.
Dr. James Beck 00:42:17
Yeah, thanks, Michael, for mentioning that, and I think that's you know, brings up a really good point. Is that you know these are goes back to your original statement. This is our foothold into understanding the biology of Parkinson's disease, this cleat, if you will, and can really allow us a nice jumping off point to you know hopefully bring real change for people with Parkinson's. And I take this moment to. Remind our viewers that in cystic fibrosis, the first cure that came only helped two percent of those living with CF. Now they have medications which help 95 percent of people with CF.And so I, I think we should always recognize that we'll have our first therapy that will really make a difference, maybe for a small number, but I think, and I'm curious your viewpoint, whether it can actually expand to a larger number fairly quickly. Whether you have a genetic mutation or not, maybe those therapies could be beneficial.
Dr. Michael Okun 00:43:14
Yeah, so it's interesting, and many years ago the Parkinson's Foundation actually brought in the originators of the Cystic Fibrosis Centers of Excellence, who told us this, you know, amazing story, and even watching this story unfold over a couple of decades has been amazing to see how it keeps expanding. And even at the beginning of the story, they were talking about how long people lived, and they're like,"Oh my gosh, people are living into their 30s, right? And now people are living in their 40s. Now people are living in their 50s." I mean, it is stunning, Jim. I mean, it's just an absolute stunning story.And what they did is they collected data, they collected genotypes, they began to dig in on the biology and ask these questions, and it was a conglomeration, a combination of factors, you know, for them to move, you know, this field along. But once they got that cleat in the ground, and once they started to go, it really changed the entire landscape for anybody living with cystic fibrosis. Cystic fibrosis now, you know, like you know, my kids, you know, growing up, you know, and leaving the house. Cystic fibrosis from when they were born to now that they're going to college is a completely different disease.
And so you know the hope is that Parkinson's disease can follow in that same trajectory. But you know there are some complexities that make Parkinson different than cystic fibrosis in terms of the you know the genetic abnormality. What we call homogeneity, how similar groups are, the heterogeneity in the in the group of folks that have cystic fibrosis, and so there are differences in that, and we think through those differences, and I think that it's important for us to learn from that.
But also, you know, that we take smaller bites of the apple, so to speak, and so, so, and I think the Parkinson's Foundation, many other foundations, NIH, and everything. I think we are taking smaller bites of the apple, putting the pieces of the puzzle together, and it's going to be trickier than cystic fibrosis. But I think it's a doable equation.
Dr. James Beck 00:45:17
Yeah, I think it goes back to that phrase you said at the beginning that you know we need to become a little more chastened in our hubris and what we think we can accomplish, and so moving with small bites can get us there. I think maybe even faster. So when we think about, as you talked about, you know these groups and different types, it makes me think about the trials that are going to be necessary to do that. You know, when we what does it take to like actually you know develop these kinds of drugs? I mean, what are the kind of clinical trials? What are kind of typical?You in your experience you've seen for some of these trials, what is the ideal candidate? I know every trial is always a little bit different, but you know, what are we thinking about is for people to participate in clinical trials.
Dr. Michael Okun 00:46:10
Yeah, so first of all, it's really important that folks participate. Second, I would say the single biggest thing that some of the recent studies have taught us is two things: one, humility, and two, persistence. Okay, I think those are really, really important. And I would say that one of the things that we can do better is to make sure we look in the mirror, and there's a great story that we had written about with Chuck Adler looking in the mirror at his own career as he took his last lap around the track with the Mayo Clinic, and just thinking about like what the gods of Parkinson told him, what he thought would happen in his career, what he wanted to happen for his grandfather, and what didn't happen, and why that didn't happen, and so I think humility and persistence are important, but I still think that Chuck was an important part of the story, and all of Chuck's work have been amazing.Everything from pathology to clinical trials. So when we think about you know the clinical trials, we have to think about you know the fact that Parkinson's biology it's not a simple plumbing problem, okay? And we have to think about you know the heterogeneity you know of our of our groups you know that they can be very different, and that's where sometimes the genetic groups, although harder to recruit, can be quite nice because they can allow you the opportunity to be able to be cleaner and to have more what we call homogeneity, you know, across. Although even within the genetics, there are differences between them.
And I think that we have to be encouraged by the convergence of the science and the research, rather than looking at you know one favorite horse. Okay, if we think about trials that are thinking about the why, you know the biomarkers, the precision genetics, the application of targeting pathways, whether it's synuclein or not, are you going after lysosomal pathways? And then, what form of study are you are you thinking about and making sure that study is designed in such a way that it is going to give you an answer? Now, people may want the answer for the third bucket, the cure answer, but I would say.
The history has told us we need to be more measured, and we need to try to work to that answer. That's going to be, you know, more important for us to be thinking about getting the steps on that ladder, the bites of that apple. So when they add up, they'll synergize, and we'll be able to change the field. The clinical trialists groups of them with the Parkinson Study Group are great. Have been worked with Parkinson's Foundation Centers of Excellence on you know various of these studies. But I think it's really important to dig in on who do you want to study, why do you want to study them, you know, not taking too big of a bite of the apple.
We've learned how that can you know that can you know backfire on us, but also considering that when we go from smaller groups, we can expand the therapy into larger groups. We've been much better at this in device-based therapies in my own lab and developing this. And you think, how do we go from a handful of these people to affecting an entire generation of people with different diseases, and we've been able to think through that with neuromodulation and other therapies. I think we have to just be a little bit more measured, take our lumps of what we have learned, but also I think that there is a method, and we've got to draw more.
Dr. Michael Okun 00:49:38
More industry in with us, so we need more industry partners. Just like cancer, we've got to have the right partnerships, and we've got to think about combinations of therapies, and that's where we really need our trialists. You look at cancers, you look at other fields, you look at HIV. Combinations of therapies are probably going to be in our future here, and so we need to start thinking about how we're going to do that. Might be hard. There are hard things that we're going to have to tackle. That's hard. What's the timing of any therapy? How heterogeneous is your population? How are you going to measure it? These things are really important.So, really hats off to everybody who volunteers for clinical trials. Keep volunteering. We need you, and our failures are what we need for successes. And if you want proof of that, ask Thomas Edison from the grave how many times he failed before he got that light bulb to turn on.
Dr. James Beck 00:50:30
A lot, yeah, a lot of times, hundreds, if not more. Well, looking at the time, we've had a really good conversation, and I want to open it up to get some of the input from our listeners who are coming in, if I may, and just transition to that. So, let me ask you some of the questions that are coming in. This one is from Jim, not my namesake directly, so it's not me sneaking this question in. It's one of our listeners. And Jim is asking, "Should I be open to participating in a clinical trial, and how do I evaluate whether it's the right choice for me?"Dr. Michael Okun 00:51:05
Yeah. So thanks, Jim. The answer is yes. You should always be open. The second thing is, remember, clinical trials often will require quite a bit of time and effort and dedication, and they can be quite boring. And I often give the boring thing. I'm going to make Dr. Beck laugh here, but it turns out that one of the things when I talk to folks about trials, particularly early-phase device trials in my lab for various diseases, is a lot of times it takes us a long time to download the brain, and you have to sit around, and it's pretty boring. And so that commitment: How close do you live to a site?Sometimes we have people coming from different continents, different areas of the United States. I happen to live in the United States, but this applies to anybody listening from anywhere all over the world. How much do you have to travel? Are you able to do this? Do you have the resources and the time to invest in the trial?
And then making sure that you are completely committed to the trial, meaning it's probably not a good idea to talk to other people that are in the trial and get on social media and all those things, and to let the trial run its course so we can get the results and so they're not tainted for the rest of the field. If you feel like you have some symptoms that qualify you, no matter if it's a behavioral therapy, a pharmacologic therapy or a surgical therapy, risks and benefits are really important. And have that dialogue with your docs and also with your spouse and with your caregiver.
If you can work it out and do the trial, that's great. That's terrific. We are in desperate need of people to get involved with trials, but we also don't want you to get involved if it's something that you can't finish. We want to make sure that we can get people who are able to finish it, so we can get to that result sooner. And so I think there are lots of exciting things, but you should not always be drawn to the most shiny object. And so sometimes, because there's a bit of, I'm going to use the word, desperation when you have a disease. I'm just going to say it out loud because I think it's important.
Don't be drawn to a clinical trial because of desperation, and don't put all of your marbles on it so that you end up feeling very sad, depressed. And I told you the story about people getting the stem cell transplants from overseas. It's a process, and sometimes participating in the clinical trial benefits you, and sometimes it doesn't. And there's a beautiful picture at Fixel of the hands, the adult hands and the children's hands and the world in between them, in our clinical trial center.
And we always remind people that when you volunteer for a clinical trial, that generation that volunteers, it might help you. But the collective of people doing this is definitely going to help that next generation of younger hands. And so, just remembering that is important.
Dr. James Beck 00:53:50
Yeah, I agree 100%, and I think that's really a good perspective on that. So, how would someone, and this is a common question from Mickey, how do they learn about taking part in a study? And is this something you go to your neurologist about, or would you go online? And how do you find out about new ones that are going to be in your area?Dr. Michael Okun 00:54:14
Just going to move locations here so I can make sure I get quiet here. So, a couple of things that I think are really important. You can see I'm dual-tasking now, which is hard in Parkinson's. Also hard for university professors like me. So, one of the most important things is to make sure that when you're thinking about a clinical trial, that you know about a website. I mentioned it once before. It's called ClinicalTrials.gov. It's where most of the trials are registered. Now, in some countries, there's a registration that goes through their country, so there can be alternatives. But you want to look for something that's registered.It doesn't mean that it's actually legitimate, or that it makes sense, or that it makes sense for you. And so, don't be completely blinded by this idea that just because you see it in print, or just because you read an article on it, or just because it appears on one of these registries, that it's completely legitimate. But that should be step one. Second, look at where the locations are relative to you. Is this feasible for you to be part of the trial? And both for you, who wants to be in the trial, but also is it fair to those investigators? Are you going to be able to give them what they need and the number of visits over that time?
And then the last thing is, don't be completely disappointed. Let's say you live too far, or there's some reason, or your spouse or your caregiver needs to have time to go to work, and it just can't work out for you. Don't be completely disappointed because guess what? If it comes to something, it'll move on to the next phase, and then eventually it'll get its regulatory approval, and you'll get access to it at some point down the road, if you are a candidate for that.
But some people feel really guilty, like, "I can't get into a trial because my spouse or my caregiver can't get me there. I don't have the finances. I live too far away." We love the fact that you want to get into a trial, but don't beat yourself up. If you can do it, great. If you can't do it, it's okay. Just the idea that you're still promoting and thinking about it is really important.
Dr. James Beck 00:56:20
Yeah, I think that's a really good point. And I think it goes to this next question too, because we're thinking about the hope and where we can go. Geraldine is asking, based upon our conversation, it sounds like it's going to take decades to find therapies or treatments to modify progression. Do you think there's hope within the next five years we'll see something turn the corner on where we are with the disease?Dr. Michael Okun 00:56:46
Yeah, so I think that there is definitely hope. I think that we always have to be careful with reality. I do think that there's plenty of research and plenty of experience that shows that we can be realistic when we talk to people. You and I, Dr. Beck, we can talk, we can have these conversations. We should be realistic with people about where we are. But that doesn't mean that we shouldn't have hope.I think we have to be very careful with timelines and measured with timelines, and this idea of five-year timelines has sort of run its course to being annoying for a lot of people that are in the field, particularly scientists and family members and people that keep getting promised at the five-year mark that there's going to be something. Having said that, we have a lot of trials that are moving into what's called phase three. Those are kind of the most important final safety-and-does-it-work-together types of trials, and we're seeing some new therapies sort of working their way through.
So, will you see new therapies in the next five years? Yes, you will definitely see some therapies. Are you going to get a breakthrough? Are you waiting for a breakthrough? Maybe. It really depends on how you define a breakthrough. But to us, we're thinking about breakthroughs as things that can meaningfully change your life. So do not put your life on hold. I'm going to say that again: Do not put your life on hold for a quote, breakthrough. There are still many meaningful things that are going to happen in the next five years in mobility, in mood, in sleep, in cognition and in quality of life.
Stay active, optimize your treatments, think about whether clinical trials are right for you, and we are going to see changes. But don't put your life completely on hold. It's really important to have perspective, and we'll walk the road for you. And I just want to mention that I think the best, and I'm completely biased here, Dr. Beck, so just I'm out the door on this one, but the best place for information is the 1-800-4PD-INFO Helpline that the Parkinson's Foundation has run for many years.
It used to be an online Ask the Doctor forum and Ask the Expert forum, but now there are real people that pick up the phone, and they're fantastic. And so, if you need somebody to talk to about any of these things, it turns out in the medical field, sometimes they barely have five minutes for you. And so this is a really wonderful resource that the Parkinson's Foundation has, and they're all various multidisciplinary experts and can talk you through a lot of these things. And remember that the number, when I say 1-800-4PD-INFO, for those of us that are old enough, if you look at the telephone, the numbers also have letters next to them, and that's why it can spell 1-800-4PD-INFO. But yeah, don't put your life on hold. But definitely have hope. But be careful of the five-year window.
Dr. James Beck 00:59:42
Yeah, thanks, Michael. I appreciate the shout-out to my colleagues on the Helpline. They're fantastic, incredibly knowledgeable and there to help everybody. And just a reminder, our chatbot, our Parkinson's PAM chatbot, is there for those who can't reach us during off-hours. It has comprehensive resources that Dr. Okun himself and his colleagues have helped put together for individuals.So, as we talk about these DMTs and we think about where a person is within their disease, I think it's really important, as you said, you can't put your life on hold waiting for things to happen. I mean, today there's a new iPhone out, but if you keep waiting for the iPhone, you could be waiting a long time for the next one. So you just kind of have to work with what you have today. So when we think about these DMTs, for someone with early Parkinson's versus advanced, do you think they're going to work differently, or do you think you'll see a similar result? This is another question that's come in from our listeners.
Dr. Michael Okun 01:00:41
Wow, that is a really insightful question, and we should put that person... By the way, something we didn't do 20 years ago, which was a big mistake, was have persons with the disease on the panels helping us to design studies and at our meetings, and now we do this routinely. And so this is why, because of questions like this. When you think about the design of a disease-modifying therapy, you are unfortunately going to have to, with regulatory agencies, whether it's the FDA or another regulatory agency in another country, decide your group.Parkinson's as a disease is so heterogeneous in terms of different genes and different things along the road. You've got to control for as many factors as you can in a trial, and so for a disease-modifying trial, you're probably going to have to decide what type of disease modification you're doing and whether you're going to do it on early, mid or late, and how you define that. There can be a lot of different ways that is defined.
And so it will probably start with a smaller bite of the apple, and you could waste a lot of money, we've learned, by trying to bite that apple, the whole thing, off all at once. And so it's super disappointing. And I'm just going to share with you how many people I've met, and they say, "I really want to be in this study, and I don't qualify for the study because the FDA or the investigators decided that it had to be a cutoff here of disease duration, or it had to be a cutoff for their age, or it had to be a cutoff." And my heart goes out. Really, that you want to be in the trial is awesome. But there's a reason for that, for the long-term good. But it is super frustrating and super terrible to have to have those conversations with folks.
Dr. James Beck 01:02:30
Yeah, I think that's a good point. As we're coming towards the end of our time with you, I just wanted to think about something you've mentioned a couple of times about devices, and I'm curious. John has been listening and is asking about DBS. Do you consider that a disease-modifying therapy?Dr. Michael Okun 01:02:49
Yeah, so I don't consider DBS a disease-modifying therapy. There are actually several people in the DBS field that do believe that it has some disease modification, both based on animal studies and some early human studies. And so if it did modify the disease, I would say it's a very small amount and difficult to measure because, back to our original conversation about symptomatic versus disease-modifying, it is so powerful. So there was levodopa, right? There was dopamine, and then there was DBS. It's so powerful, it's hard to measure whether or not there's disease modification.I can tell you, because I keep reminding Dr. Beck of our age, but because of our age now, we've seen people through the life cycle of DBS, and we see that they still progress with their Parkinson's even though they have DBS. And so could there be some disease modification behind that symptomatic effect? Possible, but we think probably not a large effect. Now, we do know in the biology and the science, when we apply some of these things in our laboratories, we do know there are some really interesting things that happen scientifically and biologically with how the cells are communicating, and some of the early cells called progenitors that make everybody really excited in the laboratory.
But I can't stress enough that the laboratory hasn't made it to the human to really show that benefit.
Dr. James Beck 01:04:20
Yeah, that's unfortunate. And I know that, as you talked about, for people wanting to participate in trials, unfortunately DBS is often a reason they can't participate in trials. Unfortunately, medications are another. And so one of our listeners is asking about whether there are some trials that are looking for people who are not yet on medications for their Parkinson's disease, and they're asking whether they should stop them in order to try to get into one of these trials. What's your advice to people who are in that situation?Dr. Michael Okun 01:04:50
Well, most of the time, they're not going to allow you to stop the medications to get into a disease-modifying trial. Most of the time, it's a mistake to do that just from a management standpoint, and probably not in your best interest, too, even to try to skirt your way into the trial. So, as much as I love solving problems creatively, I probably wouldn't solve it that way for a number of reasons, medically. Having said that, we have over the years seen people torture themselves to get into these disease-modifying trials and try to avoid certain medications and get on the newest, shiniest purple pill, the fuchsia pill, the magenta pill, whatever the newest thing that's out there.And what happens is that sometimes we see tragedy unfold, and the tragedy is this, Jim. What happens is that they try so hard, and they try to stay on this medication for so long, and they torture themselves for several years, where they could have had very good living with something that's already approved and already works for their Parkinson's. And they look back and they say, "Oh my God! Why did I do that?"
And then the study didn't show that it was disease-modifying, and then they lost several years of benefit trying so hard to stay on that test or to impress their doctors. And remember, there is a power dynamic between doctors, surgeons and medical doctors, and you want to please your doctor. At least some people do. And so we have to be really careful and sensitive of that. And so you shouldn't be trying to please us.
And so the best-constructed studies, Stan Fahn was just a master at designing these studies. ELLDOPA was a very famous one. The best-constructed studies that are disease-modifying studies start with you on the disease-modifying drug but allow you to cross over to optimize medications when you need them, and not have you try not to do that. And there are some ethical issues when you do that as well. And so we can thank Stan Fahn and his colleagues and Ira Shoulson for helping us to understand that ethical quandary.
Dr. James Beck 01:07:00
Yeah, for certain. It seems to me that if you're on a medication, you're on it for a reason. So that's no reason to stop as part of that process. One final question, if I can. As we think about what the future may bring for Parkinson's and technological advances, what's on your wish list as far as that goes? Broad question, I appreciate, but still.Dr. Michael Okun 01:07:25
So I super love that question, because I think, first of all, it's great to be thinking, and we should always be thinking about that, right? You get beat down by the system, and you're no longer thinking about where things could go, what could be very cool for the next generation, and then just what's exciting you, which is always a great question to ask your doc or ask your team. Not only what's new, but what's exciting you? I think that we need to keep our eye still on alpha-synuclein.And I know some people have abandoned ship on some of these things. But I think that we should still keep an eye on aggregation and on therapies there. I think LRRK2 and the LRRK2 inhibitors. We've got to finish some of these trials. We've got to keep moving, keep advancing, keep working that, and that's from the genetic side. The GBA-targeted therapies are really important, and whether they fail or whether they succeed, we need to keep doing them. The stem cell therapies, I think, are particularly interesting. And now that they reach their next level, watch out for the peak of inflated expectations.
Remember what they can do, but also remember the promise as we get into other regions of the brain we haven't talked about, and other things like memory are really important, Jim, to people, and walking and talking and things. The gene therapies and gene editing. We didn't talk about this, but delivery of genetic materials using vectors and things in the brain, so rebuilding circuitry, protein production, editing things. Super exciting. It's coming. Some people would say it's already here. Can be used both to understand the disease and to treat the disease. We forget that about some of the gene therapies. CRISPR technologies, adaptive, smarter DBS technologies and less invasive DBS technologies.
Thinking about those rhythms, and can the brain be smart enough, and can we use the devices? And we're doing this now. We've dreamed about doing this. We're starting to do this now. There's a future for this. I think people should still keep an eye on new drugs, protein-based drugs like GLP-1 agonists. Keep your eye on those things. We haven't looked at these systems. It's one of many of the systems and targets that are in the brain, protein targets. And so there's some interesting things about this and brain health in general. And I would also encourage people that are listening today to think about your brain health.
Think about getting your low-density lipoprotein, your cholesterol, below 100. Think about whether or not you need a statin. Think about watching your hemoglobin A1c trajectory, treating diabetes early if you have it. Think about exercise and sleep, and all of those things are going to be super important to your brain health. You talk about disease modification. That may be the things we know the most about. I am excited both by focused ultrasound, both in what it's accomplishing for some people, but also its promise for less invasive therapies, even beyond Parkinson's, and what it's teaching us about the blood-brain barrier, and of course continuous infusions of medications.
Dr. Michael Okun 01:10:29
I think keep your eye on those things, and any therapy that can reduce the amount of pills that you take. That pill burden is really important. And then I would say keep your eye on the gut-brain connection. We're learning, and this is the humble pie we talked about, how much harder this is than we thought. But the trillions of different organisms that are in the gut, AI is going to help us to sort this out. Microbiome-directed therapies. Careful of nutritional overreach. If anybody tells you, "Do this..." We have a new book called The Parkinson's Plan out, and we talk a lot about nutritional overreach, where we are.But nutrition and diet are important to health, and I think there's going to be a future for the microbiome. And so these are some of the things that are exciting me, probably more than you thought. So I am a glass-half-full kind of guy on this.
Dr. James Beck 01:11:18
Yeah, I think there's a big reason to be excited about what the future holds. And so with that, Dr. Michael Okun, thank you very much. I really appreciate your time, and on behalf of everyone at the Foundation and our community, thank you again.Dr. Michael Okun 01:11:35
Yeah, pleasure. Thank you for all you're doing. Appreciate you.Dr. James Beck 01:11:39
Appreciate it. Thanks. So we had a lot of questions come in during our Q&A. Unfortunately, we couldn't get to them all, and I apologize for that. But if your question was not answered, as Dr. Michael Okun pointed out, you can call our Helpline. For those who may not be adept with the letters to numbers, it's 1-800-473-4636, or you can also email Helpline@Parkinson.org as part of that process. Our next expert briefing is going to take place October 14, and I think, as Dr. Okun mentioned, the gut-brain connection is a lot more complicated than we thought. So worth a whole hour to delve into that.We'll explore how gut health and digestion are connected to PD symptoms and overall well-being. And so you can learn more about this, as well as our other expert briefings, by just going to Parkinson.org under Expert Briefings and register for upcoming ones as well. In addition to our expert briefing series, we have our PD Health at Home series. This is where we offer a range of virtual education and wellness programs each week, and you can learn more and register at PD Health at Home by visiting the webpage Parkinson.org/PDHealth to learn more and register. Never forget, you can reach out to the Foundation. We're here 24/7 through our website, our Helpline, as well as our email.
So take care, and we'll see you at the next expert briefing.
September 9, 2026
Now, more studies than ever are exploring disease-modifying therapies (DMTs) that could truly change the future of Parkinson’s. While today’s treatments can help with symptoms, we cannot yet alter the disease progression. Researchers are working on DMTs that aim to slow, stop, or reverse the brain changes in Parkinson’s.
This session will provide an overview of where the field stands—exploring breakthroughs in cell replacement therapies, disease-modifying trials, and ethical considerations. Attendees will learn how researchers are working toward interventions that could slow, stop, or reverse the disease process.
Presenter
Michael S Okun, MD
Director, Norman Fixel Institute for Neurological Diseases
A Parkinson's Foundation Center of Excellence